Cardiovascular Outcomes With Tirzepatide Versus Dulaglutide in Type 2 Diabetes (October 2026)

01 · The short verdict

What the tirzepatide versus dulaglutide comparison tells you

It tells you whether tirzepatide was tested directly against dulaglutide on major heart and circulation events in adults with type 2 diabetes. A head-to-head design is more useful than comparing two separate trials, because both groups are studied under the same conditions.

The published paper and your diabetes team are the right places for the exact figures.

NICE has also issued guidance on tirzepatide for treating type 2 diabetes.⁸

02 · Side by side

Tirzepatide and dulaglutide compared

Your first 2.5mg pen costs £129.99 with code FIRST40 (standard price £169.99); you can see the full range on the Mounjaro pen page. Every later order is £25 off the standard price.

03 · Decision factors

Who should think about what

If you have type 2 diabetes and existing heart or circulation disease, this comparison is directly relevant to you, and the decision should be made with your diabetes team. They know your kidney function, medicines and cardiac history; we do not see that full picture from an online questionnaire alone.

If you have type 2 diabetes but no heart disease, the trial is context rather than a verdict. Day-to-day factors usually matter more: blood sugar control, side effects, how you tolerate injections, and what your prescriber recommends.

If you are researching Mounjaro for weight loss rather than diabetes, a diabetes cardiovascular trial does not answer your question.

04 · Reading the trial paper

How to read a cardiovascular outcomes trial

A cardiovascular outcomes trial asks about events such as heart attack or stroke, not just lab numbers. That makes it a different kind of evidence from a trial measuring HbA1c or weight.

When you open the paper, look at four things. First, who was enrolled: the participants' health profile tells you whether you resemble them. Second, the primary endpoint: which events were counted together. Third, whether the aim was to show the medicine was no worse than the comparator or better than it. Fourth, the confidence interval around the result, which shows how precise the estimate is.

Those questions matter more than a single headline number. A result that shows a medicine is no worse than another is not the same claim as a result showing it is better, and summaries often blur the two. If an article you read does not make the distinction clear, go back to the paper.

Finally, a trial average does not predict your own result. Individual risk depends on age, blood pressure, cholesterol, smoking, kidney health and much else that your clinician will weigh.

05 · Diabetes and the heart

Can diabetes affect your heart?

Heart health is a routine part of type 2 diabetes care, which is why cardiovascular trials exist for diabetes medicines at all. Your diabetes team will normally review heart-related risk alongside blood sugar, and can explain your personal picture.

Mounjaro is licensed for type 2 diabetes, where it improves blood sugar control and supports weight loss.¹ If you have diabetes, treatment and monitoring are coordinated differently from weight-management care, so tell your prescriber and your usual diabetes team about everything you take so care stays joined up.

For practical detail, see our guides on Mounjaro for type 2 diabetes, whether you can take Mounjaro with type 2 diabetes, and how Mounjaro can be prescribed for type 2 diabetes.

06 · How tirzepatide works

How tirzepatide helps in type 2 diabetes

Tirzepatide activates two natural gut-hormone receptors at once, GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.

This dual action distinguishes it from single-action GLP-1 medicines such as semaglutide. Most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet. For a broader look at the drug class, see GLP-1 medicines in type 2 diabetes.

Tirzepatide has a half-life of about five days, so after a final dose it takes roughly 4 to 5 weeks to clear the system. There is no way to speed this up, and nothing needs doing while it clears.

07 · Weight-loss trials, separately

Weight-loss trial results are a separate question

Heart-outcome trials and weight-loss trials answer different questions, and their numbers should not be mixed.

In SURMOUNT-1, 2,539 adults on tirzepatide alongside diet and exercise lost on average 15% of body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² For someone starting at 100 kg, 20.9% is about 21 kg. These are trial averages and individual results vary.

In the first large head-to-head trial (SURMOUNT-5), adults on tirzepatide lost on average 20.2% of body weight over 72 weeks versus 13.7% on semaglutide 2.4mg (Wegovy).¹⁵ Both are effective licensed treatments. SURMOUNT-5 compared tirzepatide with semaglutide, not dulaglutide, so it says nothing about dulaglutide.

08 · Other heart drugs

SGLT2 inhibitors, plaque and heart failure

Which medicine suits a person with heart failure depends on their diagnosis, kidney function and other treatments, so it is a decision for a cardiologist or diabetes specialist. Nobody should start or stop a heart medicine without advice from their specialist.

Ask your specialist what current guidance says for your situation.

09 · Talking to your prescriber

Questions to bring to your prescriber

The most useful way to use this trial is as a starting point for a conversation. Bring specific questions and write down the answers.

• Does my history of heart disease or heart-attack risk change which medicine is suitable?
• Which strength should I start on, and how fast should we increase it? Our guide to the Mounjaro type 2 diabetes dose explains the steps.
• How does tirzepatide compare with metformin and my other medicines? See Mounjaro vs metformin for type 2 diabetes.
• Which symptoms should make me get medical help straight away?

Report any suspected side effect through the MHRA Yellow Card scheme.¹⁹ Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines. Mounjaro is a prescription-only medicine, supplied only after an online consultation reviewed by a GPhC-registered prescriber. If you are an existing customer, our team offers ongoing monthly reviews. Ready to begin? Start your free consultation, or browse all weight loss treatments.